Associate Professor Meg Jardine
Conjoint Associate Professor

Associate Professor Meg Jardine

MBBS (Hons I) (University of Sydney), 1995

Fellow of the Royal Australian College of Physicians, 2002

PhD, (University of Sydney), 2008

Medicine & Health
School of Biomedical Sciences

Professor Jardine is the Director of the University of Sydney NHMRC Clinical Trials Centre, and a Professor of Medicine at the University of Sydney.  She holds a Conjoint position with UNSW and an Honorary appointment at The George Institute. Prof Jardine a is a practising physician at Concord Repatriation Hospital. Her research has focused on investigating the progression and complications of non-communicable diseases, particularly kidney disease and diabetes, through randomised trials and epidemiological analyses. Prof Jardine has a particular interest in expanding the use of innovative and cost-effective methodologies to increase the generation of high-quality evidence. She is an experienced leader of trial collaborations focussing the on improving outcomes for people living with chronic kidney disease or diabetes, or experiencing COVID-19 infection. Prof Jardine is involved in national and international guidelines and policy development with roles including Executive Member of the international KIDGO nephrology guidelines committee, Board Member of the Kidney Health Initiative (collaboration of the American Society of Nephrology, FDA and other stakeholders), Board member of ACTA and member of the Research Advisory Committee to the national nephrology association (ANZSN). She is incoming Chair of the International Society of Nephrology Advancing Clinical Trials (ISN-ACTs) Group and has served as Deputy Chair of the Scientific Advisory Committee of the Australasian Kidney Trials Network (AKTN). Prof Jardine has led the curriculum of international conference streams and satellite programs for the World Congress of Nephrology. In 2020 she was honoured to receive the ANZSN TJ Neale Award for Outstanding Contribution to Nephrological Science.

Phone
0280524500
Location
Sydney
  • Journal articles | 2022
    Lv J; Wong MG; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Jardine MJ; Reich HN; Cattran D; Glassock R; Levin A; Wheeler DC; Woodward M; Billot L; Stepien S; Rogers K; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V, 2022, 'Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial', JAMA - Journal of the American Medical Association, vol. 327, pp. 1888 - 1898, http://dx.doi.org/10.1001/jama.2022.5368
    Journal articles | 2021
    Wong MG; Lv J; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Reich HN; Cattran D; Glassock R; Levin A; Jardine MJ; Wheeler DC; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V, 2021, 'The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics', American Journal of Nephrology, vol. 52, pp. 827 - 836, http://dx.doi.org/10.1159/000519812
    Journal articles | 2020
    Krishnasamy R; Hawley CM; Jardine MJ; Roberts MA; Cho Y; Wong M; Heath A; Nelson CL; Sen S; Mount PF; Pascoe EM; Vergara LA; Paul-Brent PA; Toussaint ND; Johnson DW; Hutchison CA, 2020, 'A trial evaluating mid cut-off value membrane clearance of albumin and light chains in hemodialysis patients: A safety device study', Blood Purification, vol. 49, pp. 468 - 478, http://dx.doi.org/10.1159/000505567
    Journal articles | 2019
    Jardine MJ; Li N; Ninomiya T; Feng X; Zhang J; Shi J; Zhang Y; Zhang R; Zhang J; Hao J; Perkovic V; Heerspink HL; Wu Y; Yan LL; Neal B, 2019, 'Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial', Journal of Renal Nutrition, vol. 29, pp. 276 - 284, http://dx.doi.org/10.1053/j.jrn.2018.10.009
    Journal articles | 2019
    Liao JL; van den Broek-Best O; Smyth B; Hong D; Vo K; Zuo L; Gray NA; Chan CT; de Zoysa J; Perkovic V; Jiang L; Jardine M, 2019, 'Effect of extended hours dialysis on sleep quality in a randomized trial', Nephrology, vol. 24, pp. 430 - 437, http://dx.doi.org/10.1111/nep.13236
    Journal articles | 2017
    Lv J; Zhang H; Wong MG; Jardine MJ; Hladunewich M; Jha V; Monaghan H; Zhao M; Barbour S; Reich H; Cattran D; Glassock R; Levin A; Wheeler D; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Wang HY; Perkovic V, 2017, 'Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial', JAMA - Journal of the American Medical Association, vol. 318, pp. 432 - 442, http://dx.doi.org/10.1001/jama.2017.9362
    Journal articles | 2015
    Wang AY; Bellomo R; Cass A; Finfer S; Gattas D; Myburgh J; Chadban S; Hirakawa Y; Ninomiya T; Li Q; Lo S; Barzi F; Sukkar L; Jardine M; Gallagher MP, 2015, 'Health-related quality of life in survivors of acute kidney injury: The Prolonged Outcomes Study of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy study outcomes', Nephrology, vol. 20, pp. 492 - 498, http://dx.doi.org/10.1111/nep.12488

  • 2020-2021 

    MRFF Respiratory Medicine Clinical Trials Research on Covid-19 Grant (APP2002277); Repurposing existing medications to reduce severe acute respiratory distress in patients with COVID-19: the CLARITY trial. CIA; AUD$1,406,587

  • 2019-2024  MRFF Project Grant (APP1170281); Better Evidence and Treatment for Calciphylaxis (BEAT-Calci) .  CIA; AUD $2,191,749.30
  • 2019-2024  NHMRC Project Grant (App 1162375): Treatment of cardiovascular disease with very low dose Rivaroxaban in Advanced Chronic Kidney disease (The TRACK Trial) .  CIC; AUD $5,522,418
  • 2018-2019  NHMRC Project Grant (APP 1148060) Kidney function and the effectiveness and safety of direct oral anticoagulants in atrial fibrillation: the KODIAK-AF Study.  CID; AUD $445,494
  • 2017-2021  NHMRC Project Grant (APP 1127085): Evaluation of the efficacy and safety of health service dialysate sodium practice on clinical outcomes.  CIA; AUD $1,958,205 
  • 2017-2020 Canadian Institutes of Health Research SPOR Innovative Clinical Trial Multi-Year Grant.    Co-investigator, CA $2,970,675
  • 2017-2022  HRC 16/425 Pragmatic Clinical Trial of sodium Lowering in Dialysate.  Named Investigator 2, NZ $1,199,789
     

TJ Neale award for contributions to nephrological science, 2020.

KHA Clinical Science Award, Australian and New Zealand Society of Nephrology (ANZSN) Annual Scientific Meeting (ASM), Melbourne Australia, 2014

John Chalmers Award for best original paper by a post-doctoral fellow, 2010

Finalist: Kidney Health Australia Clinical Research Award. Australia and New Zealand Society of Nephrology Annual Conference 2010.

Finalist: Young Investigator’s Award, ANZSN ASM, 2005, Wellington, NZ

Young Investigator’s Award, TSANZ conference, 2004

GlaxoSmithKline Travel Award for Research in Transplantation, Awarded at TSANZ conference, 2001

Young Investigator’s Award, TSANZ conference 2001

University of Sydney Union Phillips Fox Leadership Prize – ‘for leadership excellence in service to the wider university community’, 1992

Welch Allyn prize – ‘for person who has contributed most to the year’ elected by secret ballot of Med 3 students, 1991

My  research interests centre on the use of innovative and cost-effective methodologies to investigate the impact of pharmaceutical, device and health service interventions on outcomes for people with chronic disease. My research has focussed on investigating the progression and complications of kidney disease and diabetes through epidemiological analyses of large scale datasets and the development and implementation of randomised clinical trials.